BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/24/2021 9:48:20 AM | Browse: 695 | Download: 1366
 |
Received |
|
2021-07-29 09:22 |
|
Peer-Review Started |
|
2021-07-29 09:28 |
|
First Decision by Editorial Office Director |
|
2021-11-07 21:02 |
|
Return for Revision |
|
2021-11-07 21:02 |
|
Revised |
|
2021-11-18 09:27 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-12-09 03:41 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-12-10 02:42 |
|
Articles in Press |
|
2021-12-10 02:42 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-12-17 04:01 |
|
Publish the Manuscript Online |
|
2021-12-24 09:48 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Strategy for the control of drug-induced liver injury due to investigational treatments/drugs for COVID-19
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ken Sato, Yuichi Yamazaki and Toshio Uraoka |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ken Sato, MD, PhD, Associate Professor, Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511, Gunma, Japan. satoken@gunma-u.ac.jp |
| Key Words |
Coronavirus disease 2019; Drug-induced liver injury; Cytochrome P450; Drug-drug interaction; Drug-disease interaction; Cytokine |
| Core Tip |
To cope with dysregulation of liver function in coronavirus disease 2019 (COVID-19), drug-induced liver injury (DILI) due to investigational treatments/drugs or drug-drug or drug-disease interactions should be considered. We described useful information associated with clinical practice. We discussed the potential hepatotoxicity of dexamethasone or remdesivir as representative investigational treatments/drugs for COVID-19. These drugs are predicted to be used for a certain time in monotherapy or combination therapy. We also reported glycyrrhizic acid and ursodeoxycholic acid as therapeutic candidates for the control of DILI due to investigational treatments/drugs, as well as COVID-19. |
| Publish Date |
2021-12-24 09:48 |
| Citation |
Sato K, Yamazaki Y, Uraoka T. Strategy for the control of drug-induced liver injury due to investigational treatments/drugs for COVID-19. World J Gastroenterol 2021; 27(48): 8370-8373 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i48/8370.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i48.8370 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
